CRISPR Therapeutics AG - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CRISPR Therapeutics AG on November 8, 2018. The report discloses a specific corporate event occurring on the same date regarding a strategic collaboration.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a share issuance event.
Material Changes
On November 8, 2018, the Company issued 214,512 common shares to ViaCyte, Inc. This issuance was executed pursuant to a Research and Collaboration Agreement dated September 17, 2018. The shares were issued under the Company's effective shelf registration statement on Form S-3 (File No. 333-221491).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It does not disclose specific risks or contingencies beyond the legal opinion regarding the share issuance attached as Exhibit 5.1.
Key Facts for Investor Verification
- 214,512 common shares were issued to ViaCyte, Inc. on November 8, 2018.
- The issuance stems from a Research and Collaboration Agreement signed on September 17, 2018.
- The transaction utilized the Company's existing Form S-3 shelf registration.
- No financial performance data is included in this specific filing.